Laura Goff, MD, MSCI, associate professor of Medicine, has been named the executive medical director for the Vanderbilt-Ingram Cancer Center (VICC) Cancer Patient Care Center.

Wade Iams, MD, MSCI, assistant professor of Medicine, is the recipient of a National Comprehensive Cancer Network Foundation Young Investigator Award.

People with inoperable anal cancer treated with carboplatin-paclitaxel had fewer complications and lived longer than those who received another chemotherapy that has been more often administered.

David Cortez, PhD, has been named associate director for Basic Science Research at Vanderbilt-Ingram Cancer Center (VICC).

More than a dozen representatives of Vanderbilt University Medical Center helped plan and made a commitment to help carry out the strategy for how Tennessee will prevent cancer and minimize its burden on state residents.

A team of Vanderbilt researchers constructed polygenic risk scores (PRS) based on genomic variants associated with eight common cancers and concluded they could potentially be used for personalized risk assessments.

A drug combination effectively killed aggressive blood cancers in cell and animal models; now it’s being tested in patients.